Cstone Pharmaceuticals Co. Ltd. is an investment holding company, which engages in the research and development of complex biopharmaceutical products and sale of pharmaceutical products. The company is headquartered in Suzhou, Jiangsu and currently employs 131 full-time employees. The company went IPO on 2019-02-26. Through its subsidiaries, the Company is primarily engaged in the research and development of biopharmaceutical products, sale of pharmaceutical products and provision of license of its intellectual property (IP) or commercialization license. The Company’s main products include targeted therapies, AYVAKIT (avapritinib) and GAVRETO (pralsetinib). The firm is also involved in the development and commercialization of immuno-oncology. The firm mainly conducts its businesses in the domestic market and overseas markets, such as Central and Eastern Europe and Switzerland.
Follow-Up Questions
CStone Pharmaceuticals 的 CEO 是誰？
Dr. Jianxin Yang 是 CStone Pharmaceuticals 的 Chief Executive Officer，自 2016 加入公司。
CSPHF 股票的價格表現如何？
CSPHF 的當前價格為 $0，在上個交易日 decreased 了 0%。
CStone Pharmaceuticals 的主要業務主題或行業是什麼？
CStone Pharmaceuticals 屬於 Biotechnology 行業，該板塊是 Health Care
